Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

The recalled drugs comprised semaglutide, which belongs to the GLP-1 class of drugs, and pyridoxine, which is a form of vitamin B6. “The product was produced with an unauthorized active ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...

Is Compounded Semaglutide Effective for Weight Loss? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Is compounded semaglutide effective for weight loss? Here’s the short ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes (T2D). Current ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Once opened, compounded semaglutide typically lasts 28 days in the fridge. Compounded semaglutide, which contains the same active ...

Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a ...

But even the compounded form, which at one point cost Rice $499, was expensive. She stopped using semaglutide and gained 26 pounds Rice started taking weekly injections of semaglutide in May 2022.

Treatment with once-weekly semaglutide 7.2 mg conferred a 20.7% weight reduction vs. a 17.5% weight loss with semaglutide 2.4 mg. The safety profile of semaglutide 7.2 mg is similar to other GLP-1s.

This week, Novo Nordisk announced that people taking its mega-dose version of semaglutide lost substantially more body weight than usual in a large-scale trial. Novo Nordisk’s STEP UP trial ...

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...